Evidence map›Paper›PMID 25884820›Full record

ArticleDiagnostic pathology2015

Prognostic impact of vascular invasion and standardization of its evaluation in stage I non-small cell lung cancer.

Rurika Hamanaka, Tomoyuki Yokose, Yuji Sakuma, Masahiro Tsuboi, Hiroyuki Ito, Haruhiko Nakayama, Kouzo Yamada, Ryota Masuda, Masayuki Iwazaki

Open access · goldAbstract read
In one paragraph

Article in Diagnostic pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Rurika HamanakaDepartment of Thoracic Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan. rurika.hamanaka@gmail.com.
Tomoyuki YokoseDepartment of Pathology, Kanagawa Cancer Center Hospital, 2-3-2 Nakao, Asahi-Ku, Yokohama, Kanagawa, 241-8515, Japan. yokose-t@kcch.jp.
Yuji SakumaDepartment of Pathology, Kanagawa Cancer Center Hospital, 2-3-2 Nakao, Asahi-Ku, Yokohama, Kanagawa, 241-8515, Japan. sakuma@sapmed.ac.jp.
Masahiro TsuboiDivision of Thoracic Surgery, Respiratory Disease Center Yokohama City University Medical Center, 4-57 Urafune, Minami-Ku, Yokohama, Kanagawa, 232-0024, Japan. mtsuboi@east.ncc.go.jp.
Hiroyuki ItoDepartment of Thoracic Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan. h-ito@kcch.jp.
Haruhiko NakayamaDepartment of Thoracic Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan. nakayama-h@kcch.jp.
Kouzo YamadaDepartment of Thoracic Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan. yamadak@kcch.jp.
Ryota MasudaDivision of General Thoracic Surgery, Department of Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. masudar@is.icc.u-tokai.ac.jp.
Masayuki IwazakiDivision of General Thoracic Surgery, Department of Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. Iwasaki@is.icc.u-tokai.ac.jp.
Kanagawa Prefectural Hospital Organization · JPTokai University · JPKanagawa Cancer CenterYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with pathologic stage (p-Stage) IA non-small cell lung cancer (NSCLC) have a good survival rate because of possible curative resection. However, up to 10% of these patients relapse postoperatively. To identify unfavorable prognostic factors, we retrospectively analyzed the clinicopathological features of p-Stage IA disease, focusing on vascular invasion.

methodsOf 467 patients with p-Stage I NSCLC, 335 were diagnosed with p-Stage IA or IB disease based on a lesion size ≤3 cm and the presence of pleural invasion (PL). Univariate and multivariate analyses of recurrence-free survival (RFS) were performed with age, sex, PL, and vascular invasion (blood vessel invasion [v] and lymphatic vessel invasion [ly]) as variables. To examine vascular invasion, hematoxylin-eosin (HE), Elastica van Gieson staining, and immunostaining with anti-podoplanin antibody were performed. The presence or absence of v and ly was recorded; the number of involved vessels was counted. Survival rates were obtained using the Kaplan-Meier method and log-rank test. Multivariate analyses were performed using the Cox proportional hazards model.

resultsRFS differed significantly between patients with no or one involved blood vessel (0 v or 1 v) and those with ≥2 involved vessels (≥2 v). Similarly, RFS differed significantly between patients with no lymphatic vessel involvement (0 ly) and those with one involved lymphatic vessel (1 ly). Thus, BVI(+) and BVI(-) were defined as ≥2 v and 0 v + 1 v, and LVI(+) and LVI(-) as ≥1 ly and 0 ly, respectively. BVI and LVI together represented tumor vessel invasion (TVI). On multivariate analyses, PL and TVI were independently associated with recurrence. Additionally, patients with p-Stage IA TVI(+) disease had a comparable recurrence rate to those with p-Stage IB disease.

conclusionsSimilar to PL, TVI is an important factor increasing the likelihood of recurrence. As HE staining alone is insufficient for evaluating vascular invasion, specific staining is necessary. Moreover, patients with p-Stage IA TVI(+) disease had a recurrence rate comparable to those with p-Stage IB disease; therefore, further studies should aim to elucidate whether patients with p-Stage IA TVI(+) disease should be administered postoperative chemotherapy similar to that received by p-Stage IB patients. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5213064891369688.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBlood VesselsCarcinoma, Non-Small-Cell LungDisease-Free SurvivalFemaleHumansImmunohistochemistryKaplan-Meier EstimateLung NeoplasmsLymphatic VesselsMaleMiddle AgedMultivariate AnalysisBiomarkers, Tumor

Identifiers

PMID25884820
PMCPMC4413537
OpenAlexW2000966098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.